Jane Street Group, LLC Madrigal Pharmaceuticals, Inc. Call Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 17, 2022	BUY	$55.89 - $101.89 $698,625 - $1.27 Million	12,500 Added 312.5%	16,500 $1.62 Million
Q4 2021 Feb 15, 2022	SELL	$72.34 - $95.09 $368,934 - $484,959	-5,100 Reduced 56.04%	4,000 $339,000
Q3 2021 Nov 16, 2021	BUY	$78.35 - $105.02 $548,450 - $735,140	7,000 Added 333.33%	9,100 $726,000
Q2 2021 Aug 16, 2021	SELL	$97.2 - $137.59 $320,760 - $454,047	-3,300 Reduced 61.11%	2,100 $205,000
Q1 2021 May 18, 2021	SELL	$108.54 - $125.2 $162,810 - $187,800	-1,500 Reduced 21.74%	5,400 $632,000
Q4 2020 Feb 17, 2021	SELL	$110.06 - $133.7 $660,360 - $802,199	-6,000 Reduced 46.51%	6,900 $767,000
Q3 2020 Nov 17, 2020	SELL	$99.78 - $124.21 $1.76 Million - $2.19 Million	-17,600 Reduced 57.7%	12,900 $1.53 Million
Q2 2020 Aug 17, 2020	BUY	$60.13 - $125.71 $1.83 Million - $3.83 Million	30,500 New	30,500 $3.45 Million
Q1 2020 May 15, 2020	SELL	$66.76 - $93.49 $166,900 - $233,725	-2,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $210,700 - $296,250	2,500 New	2,500 $228,000

294

21.8M

756K

370K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $6B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.